Диссертация (1140386), страница 20
Текст из файла (страница 20)
2008. Т. 22. № 12. С. 2606–8.116.Koboziev I. et al. Role of the enteric microbiota in intestinal homeostasisand inflammation. // Free Radic. Biol. Med. 2014. Т. 68. С. 122–33.117.Koksal A.R. et al. How does a biopsy of endoscopically normal terminalileum contribute to the diagnosis? Which patients should undergo biopsy? //Libyan J. Med. 2014. Т. 9. С. 23441.118.Kostka R.
[Acute terminal ileitis and Crohn’s disease]. // Rozhl. Chir.1994. Т. 73. № 1. С. 38–40.119.Kovi J., Duong H.D., Hoang C.T. Ultrastructure of intestinal lymphaticsin Crohn’s disease. // Am. J. Clin. Pathol. 1981. Т. 76. № 4. С. 385–94.120.Kuroki T. et al. Imbalance in the stress-adaptation system in patientswith inflammatory bowel disease.
// Biol. Res. Nurs. 2011. Т. 13. № 4. С. 391–8.121.Lambrecht B. Immunologists getting nervous: neuropeptides, dendriticcells and T cell activation. Respirator Res 2001, 2: 133-138122.Lee FD, Maguire C, Obeidat W, Russell RI. Importance of cryptolyticlesions and pericryptal granulomas in inflammatory bowel disease. J ClinPathol, 1997; 50: 148-152.123.Lei S. et al. Somatostatin ameliorates lipopolysaccharide-induced tightjunction damage via the ERK-MAPK pathway in Caco2 cells.
// Eur. J. CellBiol. 2014. Т. 93. № 7. С. 299–307.124.Lemmens B, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M,Rutgeerts P, Vermeire S, De Hertogh G. Correlation between the endoscopicand histologic score in assessing the activity of ulcerative colitis. InflammBowel Dis.
2013 May;19(6):1194-201.125125.Li X. et al. Somatostatin regulates tight junction proteins expression incolitis mice // 2014. Т. 7. № 5. С. 2153–2162.126.Lichtenauer-Kaligis1 E., Somatostatin receptor subtypes in humanimmune cells. European Journal of Endocrinology (2000) 143: 21-2127.Liu Q, Cescato R, Dewi DA, et al., Schonbrunn A 2005 Receptorsignaling and endocytosis are differentially regulated by somatostatin analogs.Mol Pharmacol 68:90–101128.Lomax A.E.
et al. Effects of gastrointestinal inflammation onenteroendocrine cells and enteric neural reflex circuits. // Auton. Neurosci.2006. Т. 126-127. С. 250–7.129.MacDonald T.T. et al. What’s the next best cytokine target in IBD? //Inflamm. Bowel Dis. 2012. Т. 18. № 11. С. 2180–9.130.Magro F. et al. European consensus on the histopathology ofinflammatory bowel disease.
// J. Crohns. Colitis. 2013. Т. 7. № 10. С. 827–51.131.Magroa F,Langnerb A., et al. European consensus on the histopathologyof inflammatory bowel disease. Journal of Crohn's and Colitis (2013) 7, 827–851132.Marco Volante., Somatostatin receptor type 2A immunohistochemistryin neuroendocrine tumors: a proposal of scoring system correlated withsomatostatin receptor scintigraphy. Modern Pathology (2007 ) 20, 1172–1182133.Marszałek A. et al. Inflammatory bowel disease - is there something newin the immunological background? // Folia Histochem.
Cytobiol. 2011. Т. 49.№ 2. С. 357–62.134.Mathew RC, Weinstock JV. Granuloma formation: Inflammatory BowelDisease : from bench to bedside. Edited by Targan SR, Shanahan F.Baltimore,Williams & Wilkins, 1994, pp 151-159.135.Miller LJ. Gastrointestinal hormones and receptors. // Textbook ofgastroenterology, 3rd edn. Philadelphia, PA: Lippincott-Williams and Wilkins,1999:35–66.136.Molander P. et al. Achievement of deep remission during scheduledmaintenance therapy with TNFα-blocking agents in IBD.
// J. Crohns. Colitis.2013. Т. 7. № 9. С. 730–5.137.Molnar T, Tiszlavicz L, Gyulai C, Nagy F, Lonovics J. Clinicalsignificance of granuloma in Crohn’s disease. World J Gastroenterol 2005;11(20): 3118-3121138.Molnár T. et al. Clinical significance of granuloma in Crohn’s disease. //World J. Gastroenterol. 2005. Т. 11. № 20. С. 3118–21.126139.Molodecky N.A. et al. Increasing incidence and prevalence of theinflammatory bowel diseases with time, based on systematic review. //Gastroenterology. 2012. Т. 142. № 1.
С. 46–54.e42; quiz e30.140.Morita K. et al. Molecular architecture of tight junctions of peridermdiffers from that of the maculae occludentes of epidermis. // J. Invest.Dermatol. 2002. Т. 118. № 6. С. 1073–9.141.Mozaffari S., Abdollahi M. Melatonin, a promising supplement ininflammatory bowel disease: a comprehensive review of evidences. // Curr.Pharm. Des.
2011. Т. 17. № 38. С. 4372–8.142.Muñoz M., Coveñas R. Involvement of substance P and the NK-1receptor in human pathology. // Amino Acids. 2014. Т. 46. № 7. С. 1727–50.143.Navaneethan U. et al. Backwash ileitis and the risk of colon neoplasia inulcerative colitis patients undergoing restorative proctocolectomy. // Dig. Dis.Sci. 2013. Т. 58. № 7. С.
2019–27.144.Neurath M.F. Cytokines in inflammatory bowel disease. // Nat. Rev.Immunol. 2014. Т. 14. № 5. С. 329–42.145.Ng S.C. Epidemiology of inflammatory bowel disease: focus on Asia. //Best Pract. Res. Clin. Gastroenterol. 2014. Т. 28. № 3. С. 363–72.146.Nijhuis L.E.J., Olivier B.J., Jonge W.J. de. Neurogenic regulation ofdendritic cells in the intestine. // Biochem.
Pharmacol. 2010. Т. 80. № 12. С.2002–8.147.Nock BA, Nikolopoulou A, Galanis A, et al., 2005 Potent bombesin-likepeptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.J Med Chem 48:100–110148.O’Donnell S. et al. Isolated active ileitis: is it a mild subtype of Crohn’sdisease? // Inflamm. Bowel Dis. 2013.
Т. 19. № 9. С. 1815–22.149.Ohta H. et al. CD4+ T cell cytokine gene and protein expression induodenal mucosa of dogs with inflammatory bowel disease. // J. Vet. Med. Sci.2014. Т. 76. № 3. С. 409–14.150.Okita Y. et al. Ulcerative colitis with severe backwash ileitissuccessfully treated by staged operation without sacrificing any involvedileum. // J. Pediatr. Surg. 2009. Т. 44. № 1. С. e37–9.151.Ordás I.
et al. Ulcerative colitis. // Lancet. 2012. Т. 380. № 9853. С.1606–19.152.Overman E.L., Rivier J.E., Moeser A.J. CRF induces intestinal epithelialbarrier injury via the release of mast cell proteases and TNF-α. // PLoS One.2012. Т. 7. № 6. С. e39935.127153.Padmanabhan V, Callas PW, Li SC, Trainer T.D. Histopathologicfeatures of the terminal ileum in lymphocytic and collagenous colitis: a studyof 32 cases and review of the literature. // Mod Pathol 2003;16:115–9154.Padmanabhan V, Callas PW, Li SC, Trainer T.D. Histopathologicfeatures of the terminal ileum in lymphocytic and collagenous colitis: a studyof 32 cases and review of the literature.
// Mod Pathol 2003;16:115–9.155.Paine E.R. Colonoscopic evaluation in ulcerative colitis. // Gastroenterol.Rep. 2014. Т. 2. № 3. С. 161–8.156.Parfenov A.I. [Crohn’s disease: on the occasion of the 80th anniversaryof description]. // Ter. Arkh.
2013. Т. 85. № 8. С. 35–42.157.Pierik M. et al. Epithelioid granulomas, pattern recognition receptors,and phenotypes of Crohn’s disease. // Gut. 2005. Т. 54. № 2. С. 223–7.158.Pizarro T.T., La Rue S.A. De, Cominelli F. Role of interleukin 6 in amurine model of Crohn’s ileitis: are cytokine/anticytokine strategies the futurefor IBD therapies? // Gut. 2006. Т. 55. № 9. С. 1226–7.159.Ponder A., Long M.D. A clinical review of recent findings in theepidemiology of inflammatory bowel disease.
// Clin. Epidemiol. 2013. Т. 5. С.237–47.160.Prestifilippo A., Blanco G., Vitale M.P.,Giuffrida D. (2012).Chromogranin A and Neuroendocrine Tumors, Neuroendocrine Tumor, Dr.AnthonyLowell(Ed.),InTech,Availablefrom:http://www.intechopen.com/books/neuroendocrine-tumor/chromogranin-a-andneuroendocrine-tumors161.Prestifilippo A., Blanco G., Vitale M.P.,Giuffrida D. (2012).Chromogranin A and Neuroendocrine Tumors, Neuroendocrine Tumor, Dr.AnthonyLowell(Ed.),InTech,Availablefrom:http://www.intechopen.com/books/neuroendocrine-tumor/chromogranin-a-andneuroendocrine-tumors162.Quinson N.
et al. Effects of tumor necrosis factor α on leptin-sensitiveintestinal vagal mechanoreceptors in the cat. // Can. J. Physiol. Pharmacol.2013. Т. 91. № 11. С. 941–50.163.Reinshagen M. et al. Neuropeptides in inflammatory bowel disease: anupdate.
// Inflamm. Bowel Dis. 1997. Т. 3. № 4. С. 303–13.164.Reinshagen M., Neuropeptides in Inflammatory Bowel Disease: AnUpdate. Inflammatory Bowel Diseases 3(4):303-313165.Reubi J., Illuminating somatostatin analog action at neuroendocrinetumor receptors. Trends Pharmacol Sci. 2013 December ; 34(12)128166.Reubi J., Internalized Somatostatin Receptor Subtype 2 inNeuroendocrine Tumors of Octreotide-Treated Patients. J Clin EndocrinolMetab. 2010 May; 95(5): 2343–2350.167.Roberts PL, Schoetz DJ, Pricolo R, Veidenheimer MC.
Clinical courseof Crohn’s disease in older patients. A retrospective study. Dis Colon Rectum,1990; 33: 958-962.168.Romero M. et al. Evaluation of the immunoexpression of COX-1, COX2 and p53 in Crohn’s disease. // Arq. Gastroenterol. 2008. Т. 45. № 4. С. 295–300.169.Rosenberg L. et al. Histologic markers of inflammation in patients withulcerative colitis in clinical remission. // Clin. Gastroenterol.
Hepatol. 2013. Т.11. № 8. С. 991–6.170.Rotterdam H, Korelitz BI, Sommers SC. Microgranulomas in grosslynormal rectal mucosa in Crohn’s disease. Am J Clin Pathol, 1977; 67: 550-554.171.Rubio С.А., A Orrego, G Nesi et al. Frequency of epithelioidgranulomas in colonoscopic biopsy specimens from paediatric and adultpatients with Crohn’scolitis J Clin Pathol 2007;60:1268–1272.172.Sanders DSA. The differential diagnosis of Crohn’s disease andulcerative colitis. Baillière’s Clinical Gastroenterology, 1998; 12: 19-33.173.Sapp H, Ithamukkala S, Brien TP, et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
